Mineralys Therapeutics Charts Path After NDA Acceptance

Mineralys Therapeutics, Inc. ((MLYS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Mineralys Therapeutics’ latest earnings call carried an overall optimistic tone, as management highlighted a major regulatory milestone, a broad set of positive clinical data, and a fortified cash position that extends the company’s runway into 2028. Concerns around a missed endpoint in sleep apnea, rising operating costs, and competitive timing were acknowledged but framed as manageable within a solid path toward commercialization.

FDA Acceptance of NDA Anchors Regulatory Path

The centerpiece of the call was the U.S. FDA’s acceptance of Mineralys’ NDA for lorundrostat to treat adult patients with hypertension in combination with other drugs. With a PDUFA target action date set for December 22, 2026, investors now have a clear regulatory timeline that supports near‑term launch planning and de‑risks a critical step in the value story.

Five-Trial Program Underscores Differentiated Efficacy

Management underscored completion of five positive clinical studies, including pivotal LAUNCH‑HTN and ADVANCE‑HTN, plus EXPLORER‑CKD and the open‑label TRANSFORM‑HTN extension. Across these trials, lorundrostat delivered clinically meaningful blood pressure reductions with 24‑hour control and a favorable safety profile, reinforcing the strategy of selectively targeting aldosterone in difficult‑to‑treat patients.

EXPLORER-OSA Shows BP Benefit Despite Trial Limits

In the small 48‑patient EXPLORER‑OSA exploratory study, lorundrostat cut systolic blood pressure by 11.1 mmHg at four weeks versus 1.0 mmHg on placebo in a pre‑planned parallel‑arm analysis. A 6.2 mmHg placebo‑adjusted drop in the crossover analysis and the absence of potassium elevations above 5.5 mmol/L supported a clean safety profile, even though the trial was short and hypothesis‑generating.

EXPLORER-OSA Misses AHI Endpoint, Capping OSA Ambition

The company was clear that EXPLORER‑OSA did not meet its primary endpoint of improving apnea‑hypopnea index at four weeks. This miss likely constrains any future regulatory claim directly in obstructive sleep apnea, even if blood pressure benefits are compelling, and positions the data more as supportive of cardiovascular effects than as a standalone OSA franchise.

Study Design Constraints Temper OSA Read-Through

Management attributed some of the AHI outcome to the study’s design, which enrolled just 48 patients over only four weeks, with very severe baseline disease. Participants had a mean BMI of 38 and AHI of 48, making them a high‑risk group where short‑term anatomic or ventilatory changes are harder to demonstrate, so subgroup trends were described as hypothesis‑generating rather than definitive.

Balance Sheet Strengthens with Large Cash Infusion

Mineralys closed 2025 with $656.6 million in cash, cash equivalents, and investments, up sharply from $198.2 million a year earlier, a roughly 231% increase. Management emphasized that this balance sheet provides ample capital to complete regulatory work, run planned trials, and support commercial build‑out, extending the company’s funding horizon into 2028.

R&D Spending Falls as Pivotal Work Winds Down

Research and development expenses dropped to $132.0 million in 2025 from $168.6 million in 2024, a roughly 22% year‑over‑year decline. The reduction was largely driven by lower preclinical and clinical costs after completing lorundrostat’s pivotal program, with Q4 R&D spending of $24.4 million down more than 45% from the prior‑year quarter.

Net Loss Narrows, Reflecting Transition Phase

The company’s net loss improved to $154.7 million for 2025 compared with $177.8 million in 2024, a roughly 13% narrowing as trial spending slowed. On a quarterly basis, the Q4 net loss shrank to $32.2 million from $48.9 million in the year‑earlier period, signaling a gradual shift from heavy development outlays toward a more balanced operating profile.

Higher Cash Drives Growth in Other Income

With cash balances surging, Mineralys benefited from higher interest income on its investments and money market holdings. Other income rose to $16.0 million for the year from $14.6 million in 2024 and doubled to $6.0 million in Q4 from $2.8 million a year earlier, partially offsetting operating losses and highlighting the advantage of a strong treasury.

Commercial Build Focuses on Resistant Hypertension

The company outlined proactive commercial preparation centered on third‑line and resistant hypertension, initially targeting high‑value prescribers. Management has begun payer engagement, pre‑approval information exchange, and expanded medical affairs and MSL coverage, aiming to drive rapid uptake among roughly 60,000 physicians who write about half of advanced‑line hypertension prescriptions.

Competitive Launch Timing Adds Execution Risk

Management acknowledged that a competing product from AstraZeneca could reach the market roughly six months earlier, potentially in the second quarter of 2026. That timing gap introduces market‑share risk for lorundrostat’s eventual launch and heightens the importance of clear differentiation, physician education, and payer positioning once a label is in hand.

G&A Costs Surge with Commercial Expansion

General and administrative expenses climbed to $38.6 million in 2025 from $23.8 million in 2024, an increase of about 62%, with Q4 G&A nearly doubling year‑over‑year to $13.9 million. These higher costs reflect growing headcount, professional services, and infrastructure to support commercialization, though investors will watch whether spending scales efficiently as revenue approaches.

Unsettled Partnership and OUS Strategy Cloud Visibility

The company is still evaluating partnership options and has not committed to a final commercial staffing model or detailed ex‑U.S. strategy. Management declined to disclose current commercial team size, and overseas timelines remain fluid, leaving some uncertainty around how Mineralys will resource a global launch if a strategic partner is not secured.

Label Negotiations and International Positioning Still Evolving

While EXPLORER‑CKD data are part of the NDA, the extent of comorbidity information on the eventual label will depend on regulatory discussions, and EXPLORER‑OSA data were not included. The company also signaled that ex‑U.S. submissions may hinge on partnership talks and regional pricing dynamics, suggesting that global roll‑out strategy is still very much in formation.

Guidance Highlights Path to 2026 Decision and Launch

Looking ahead, management reiterated the December 22, 2026 PDUFA date and emphasized consistent 24‑hour blood pressure control across the five‑trial program, including the EXPLORER‑OSA BP data and clean potassium profile. The launch strategy will prioritize resistant and fourth‑line prescribers in a large U.S. market with significant unmet need, supported by ongoing payer engagement, expanded medical affairs, and a cash runway expected to last into 2028.

Mineralys’ earnings call painted a picture of a company transitioning from development to pre‑commercial stage, backed by strong clinical data and a robust balance sheet. While rising G&A, a missed OSA endpoint, competitive timing, and open partnership questions create execution risk, the accepted NDA, clear regulatory timeline, and ample liquidity keep the long‑term hypertension opportunity firmly in focus for investors.